Photo from all-can.org
Jul 9, 2023, 09:13
Cancer patients’ access to advanced genetic testing is not keeping up with the pace of discovery of targetable mutations and personalised therapies – European Society for Medical Oncology
The ESMO Study on the Availability and Accessibility of Biomolecular Technologies in Oncology in Europe published in Annals of Oncology, reveals that cancer patients’ access to advanced genetic testing is not keeping up with the pace of discovery of targetable mutations and personalised therapies.
Disparities in access were particularly pronounced for recently validated biomarkers or those requiring complex sequencing techniques. The survey results highlight the need for targeted policies to address the gaps in infrastructure and funding for Precision Oncology.
For details: Click here
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Apr 18, 2025, 20:22
Apr 18, 2025, 20:12
Apr 18, 2025, 20:03
Apr 18, 2025, 19:54
Apr 18, 2025, 19:49
Apr 18, 2025, 19:44
Apr 18, 2025, 19:26